News

Andromaco to cease and desist, from any further sales or production of Hyalocare in Mexico.

GlycoBioSciences Inc. the owner of the product, technology and patents that Hyalocare is based on, have asked Andromaco to cease and desist, from any further sales or production of Hyalocare in Mexico.

Glyco’s Canadian Patent 2,896,038, has been allowed

“GlycoBioSciences Inc. is pleased to announce, that after having its patents in the US issued/granted in 2017 and 2019, US Patents 9,821,005 and 10,322,142, that cover Glyco’s Ionic Polymer Matrix (IPM) topical delivery technology, and related products, that Glyco has been informed by the Canadian Intellectual Property Office (CIPO) (notice included), that Glyco’s Canadian Patent 2,896,038, has been allowed, and will be issued shortly”.

Canadian Market Important Notice

GlycoBioSciences Inc. (“Glyco”) is pleased to announce, that we have entered an agreement with our partner that was distributing Glyco’s IPM Wound Gel Bio (Bioferm) product in Canada, (the wound gel is licensed by Health Canada, under an NPN number as a Natural Health Product), that has terminated all rights that Robust Products Inc. had to sell the product in Canada.

All rights to sell the product in Canada have therefore returned to Glyco, and the company is now seeking a solid partner who is better equipped to sell the product in the difficult Canadian market.

GlycoBioSciences Inc. Obtains FDA Clearance for 510 (k) K123193 for bio-fermented based IPM Wound Gel

Georgetown, Ontario, Canada July 25, 2014
Press Release
GlycoBioSciences Inc. has obtained FDA clearance for their IPM Wound Gel Bio product under 510 (k) K123193 and K143527. The IPM Wound Gel Bio product treats several types of wounds/ulcers including diabetic ulcers, second degree burns, and surgical wounds (incisions and donor cites) under the supervision of a healthcare professional, and is cleared for other indications under both 510 (k)s for Over the Counter use as well.